In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...
The Motley Fool on MSN12d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its HandsIn fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will ...
Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted growth will slow this year. The Danish pharmaceutical company has ...
9don MSN
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback